ArticleNucleic acids research2025
CapBuild: a cloud-native tool for adeno-associated virus capsid engineering.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FoldaVirus, a knowledge-based icosahedral capsid prediction tool using AlphaFold.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Complete neutralizing antibody evasion by serodivergent non-mammalian AAVs enables gene therapy redosing.Cell reports. Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adeno-associated virus (AAV) capsid engineering is essential for advancing gene therapy but remains limited by structural complexity and computational constraints. To address these challenges, we developed CapBuild, a cloud-native web server that streamlines AAV capsid prediction, assembly and engineering. CapBuild provides two distinct workflows: a PDB-based pipeline for assembling complete capsids from structural files and a modelling pipeline that constructs capsids from protein sequences via SWISS-MODEL. The platform incorporates icosahedral symmetry through transformation matrices and features an integrated mutation modeller for visualising site-specific mutations across the entire capsid. Additionally, its amino acid localisation tool maps exposed and buried residues, facilitating rational design. Benchmarking against crystal structures demonstrates high structural accuracy, with consistently low RMSD values (0-0.89 Å) and high GDT scores (89.4-100%) across multiple AAV serotypes. CapBuild's interactive visualisation interface, powered by Mol*, enables in-depth structural analysis, making capsid engineering more accessible to researchers. By reducing technical barriers and automating complex modelling tasks, CapBuild facilitates early-stage AAV capsid design, enabling researchers to rationally explore and visualise structural variants for potential use. CapBuild is available at https://capbuild.csiro.au/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.